PubMed=10741911; DOI=10.1007/s004320050027
Yamamoto K., Kikuchi Y., Kudoh K., Nagata I.
Modulation of cisplatin sensitivity by taxol in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines.
J. Cancer Res. Clin. Oncol. 126:168-172(2000)

PubMed=11185891; DOI=10.1093/jjco/hyd116
Yamamoto K., Kikuchi Y., Kudoh K., Hirata J., Kita T., Nagata I.
Treatment with paclitaxel alone rather than combination with paclitaxel and cisplatin may be selective for cisplatin-resistant ovarian carcinoma.
Jpn. J. Clin. Oncol. 30:446-449(2000)

PubMed=17671176; DOI=10.1158/0008-5472.CAN-06-4567
Kikuchi R., Tsuda H., Kanai Y., Kasamatsu T., Sengoku K., Hirohashi S., Inazawa J., Imoto I.
Promoter hypermethylation contributes to frequent inactivation of a putative conditional tumor suppressor gene connective tissue growth factor in ovarian cancer.
Cancer Res. 67:7095-7105(2007)

PubMed=18319717; DOI=10.1038/sj.bjc.6604279; PMCID=PMC2275483
Goto T., Takano M., Hirata J., Tsuda H.
The involvement of FOXO1 in cytotoxic stress and drug-resistance induced by paclitaxel in ovarian cancers.
Br. J. Cancer 98:1068-1075(2008)

PubMed=18483383; DOI=10.1158/1078-0432.CCR-07-4358
Ishibashi M., Nakayama K., Yeasmin S., Katagiri A., Iida K., Nakayama N., Fukumoto M., Miyazaki K.
A BTB/POZ gene, NAC-1, a tumor recurrence-associated gene, as a potential target for taxol resistance in ovarian cancer.
Clin. Cancer Res. 14:3149-3155(2008)